Driven by Health Pharmaceutical Industry Corporate Responsibility
Contents Foreword
2
Introduction
4
Global
6
Overview
7
Local
10
Marketplace
11
Access to Medicines
11
Clinical Trials Information
11
Promotion of Medicines
12
Medicine Safety
13
Support for Patients and Patient Organisations
15
Patient Compliance
22
Community
26
Workplace
34
Further Information
38
Member Companies
39
IPHA The Irish Pharmaceutical Healthcare Association Limited (IPHA) represents the international researchbased pharmaceutical industry in Ireland. Its member companies include both manufacturers of prescription medicines and non-prescription or consumer health care medicines.
1
Foreword “ The contribution of the pharmaceutical sector to our society extends beyond the number of people employed.”
2
DRIVEN DRIVENBY BYHEALTH HEALTH
The Irish pharmaceutical industry is and has been a key player in the success and development of our economy.
The contribution of the sector to our society extends beyond the number of people employed and taxes paid to the government to all the communities around Ireland where these companies have brought outstanding practices in relation to health and safety standards, environmental care and community support. For example, the impact of the pharmaceutical industry on our educational system in terms of promoting science in education is commendable, as is the commitment of these companies to health promotion and awareness through a number of campaigns and other activities. This booklet on the responsible business practices of the members of the Irish Pharmaceutical Healthcare Association (IPHA) is the first of its kind for an industry body in Ireland and is warmly welcomed as a tool to help the wider community understand the challenges facing the industry, its commitments and
achievements. This booklet summarises a number of leading initiatives in place by businesses in the sector and provides an outlook of the key areas of concern that the industry aims to tackle. It is great to see many Business in the Community Ireland member companies actively engaged on local and national CR initiatives. We note as well that this report is published alongside Pharmachemical Ireland’s Responsible Care report covering health, safety and environmental performance. Corporate responsibility is not about additional programmes for businesses to implement but essentially about how a business is managed, how it sources raw materials, manufactures, markets, distributes and disposes of its products, how it treats its staff and customers and how it engages with the local community and society by minimising its environmental impacts. Now more than ever corporate responsibility needs to be seen as an essential element for all business success and we commend the industry for its leadership and look forward to future reports and innovative communications.
Ms Tina Roche Chief Executive Business in the Community Ireland
3
Introduction “ In addition to following a socially responsible business model, consistent with ethical global standards, companies undertake many other activities related to health care�
4
DRIVEN BY HEALTH
As far back as the development of the first pharmaceutical operations here in Ireland, pharmaceutical companies have engaged meaningfully with authorities and local communities in order to develop a business which is both profitable and sustainable. In recent years, the subject of Corporate Responsibility (CR) has become increasingly important to shareholders, Government, employees and communities. This is a welcome trend and recognises both the tangible and intangible impact that the international researchbased pharmaceutical industry can have on Ireland. Ireland has gained substantially from the presence of the pharmaceutical industry. As you will see CR is a fully integrated element of company’s strategies and operations here. This means that, in addition to following a socially responsible business model consistent with ethical global standards companies undertake many other activities related to health care. The primary societal responsibility of the pharmaceutical industry is innovation - to discover,
develop and bring to market safe and effective new medicines and vaccines for patient benefit. The products IPHA member companies make available to patients are the core of their corporate responsibility effort. They make their unique contribution through successful research and development of new medicines and vaccines. Innovation drives progress in society. In the case of pharmaceuticals, innovative research not only brings benefits for patients, improving health and quality of life, it also creates wealth and contributes to the economic development of the communities pharmaceutical companies serve. You will read in the following pages how the pharmaceutical industry, through its various initiatives individually, collectively and as part of society, has not only become a leading corporate responsibility performer in Ireland with a sustainable future, but has also emerged as a key partner alongside international aid organisations and Governments in the area of global health care.
Dr Gerald Farrell President Irish Pharmaceutical Healthcare Association
5
Global
150 78 1.75Bn $9.2Bn 67
6
DRIVENBY BYHEALTH HEALTH DRIVEN
Overview Recognising its responsibility to global health the international research-based pharmaceutical industry is committed to playing its part to help achieve the healthrelated United Nations Millennium Development Goals and to improving health around the world.
The inequality of access to healthcare remains one of the biggest challenges facing the world today. The pharmaceutical industry is aware that it has a significant role to play, but responsibility also rests with Governments and other organisations to provide appropriate infrastructures that support good public health and reliable provision of medicines and other aspects of healthcare to those in need. Pharmaceutical companies globally are currently involved in more than 150 health partnerships and programmes in the developing world which are designed primarily to improve access to medicines and other aspects of healthcare. 78 of the more than 150 disease-specific programmes involve capacity building activities, helping to reinforce healthcare systems in beneficiary countries. In the period 2000 to 2008, the industry provided enough health interventions – medicines, vaccines, equipment, health education and training – to help nearly 1.75 billion people in developing countries. The industry has made available medicines, vaccines, equipment, training and health education worth $9.2 billion, of which $2.7 billion was in 2007 alone , to the developing world since the United Nations announced the Millennium Development Goals. A number of pharmaceutical companies are involved in 67 research and development programmes, up from 58 in 2007, for neglected tropical diseases and other diseases of the developing world (DDW)* such as malaria, sleeping sickness, dengue fever and chagas disease. Pharmaceutical companies have made substantial donations to many disaster relief efforts in the recent past. These have included the Asian tsunami, Cyclone Sidr (Bangladesh), Hurricane Katrina (New Orleans), the earthquake in China and the earthquake in Peru.
2005 Medicines 32
2006
2007
2008
43
50
58
Vaccines
(uncounted) 6
8
9
Totals
32
58
67
49
*Industry DDW Research and Development – Evolution, 2005-2008
7
Global
Overview
2007 2006 2005 2004 2003 2002 2001 2000 50
100
Medicines Vaccines and Diagnostics-Donated Other health interventions+education+training Medicines Vaccines and Diagnostics-Non Profit 150
200
250
300
350
400
Millions of people reached
2005-2005
2006
2007
2000-2007
Products- Donated
903,035,262
286,376,106
267,691,783
1,457,103,151
Products- No ProďŹ t Other Healthcare Interventions
107,582,477 3,350,985
76,679,415 824,774
97,603,675 773,975
281,865,567 4,949,734
Training for health workers
192,199
52,509
53,901
298,609
Education for Patients and people most at risk
5,047,205
1,346,930
1,423,293
7,817,428
1,019,208,128
365,279,734
367,546,627
1,752,034,489
IFPMA Health Partnerships Survey 2008
8
DRIVEN BY HEALTH
Global Health Progress IPHA is a member of the Global Health Progress initiative which seeks to bring the international research-based pharmaceutical industry and global health leaders together to improve health in the developing world.
Visit: www.globalhealthprogress.org
Office of the Minister of State for Overseas Development “Ireland recognises the valuable contribution that public private partnerships involving pharmaceutical companies can and do make in low income countries. This is borne out in our first hand experience of support to a number of global PPPs developing new and better drugs and diagnostics for diseases of poverty, especially HIV & AIDS, tuberculosis and malaria. Your interest in global health and health in developing countries is encouraging.” 22 May 2007
© BMS - www.securethefuture.com ®
9
Local
10
IPHA Corporate Responsibility booklet 2009 DRIVEN BY HEALTH
Marketplace It remains our goal to ensure that our contribution to medical science reflects our commitment to safe and healthful workplaces, strongly supported communities and patients in everything we do, from research and development to sales and marketing. Every activity the pharmaceutical industry is involved in revolves around patients. Our commitment to meeting the needs of patients is paramount. It is our role to meet their needs and provide them with new and better medicines to treat disease. Only by placing the patient at the centre of everything we do can we meet our societal responsibilities and maintain a profitable and sustainable business.
Access to Medicines
Clinical Trials Information
The pharmaceutical industry recognises that the growing demand for healthcare means increasing pressure on the Exchequer. The pharmaceutical industry is committed to working with the State to ensure that patients have access to the full range of therapeutically advanced medicines, irrespective of their ability to pay, and has worked with the Department of Health & Children and the Health Service Executive (HSE) to achieve this objective. In September 2006 an Agreement was reached between the IPHA and the HSE which ensured that patients would continue to have access to the most up to date and highest quality medicines when they need them. This was good news for Irish patients.
The clinical development (testing in humans) of a potential new medicine is a significant undertaking, including extensive collaboration with doctors in many countries and involving many thousands of people (both healthy volunteers and patients). They are conducted to evaluate the safety and efficacy of medicines as they are developed and after they reach the marketplace.
This partnership continues to support and encourage innovation which is the primary societal responsibility of the pharmaceutical industry, the key to the improvement of our healthcare system, patient health and Ireland’s economic development.
professionals get greater aware-ness and accessibility to information about medicines in development. Prompt and open disclosure to patients and doctors has been recognised as a responsibility for every company, particularly when the information involved may affect the health of a patient.
In 2006, recognising that there are important public health benefits associated with the wider dissemination of clinical trial information and committed to making information on ongoing clinical trials publicly accessible, the pharmaceutical industry created a single Internet portal so that the public could easily access information about ongoing clinical trials and results of those trials, whether positive or negative. Updated within 21 days of the commencement of a new trial, the IFPMA Clinical Trials Portal ensures that the public and healthcare
Visit: www.ifpma.org/clinicaltrials
11
Local
Promotion of Medicines The pharmaceutical industry has a responsibility to inform doctors and healthcare workers about the medicines it develops. The pharmaceutical industry provides healthcare professionals with education programmes and communicates with them regularly on the causes of disease, their prevention and treatment. The information provided to health professionals helps them to make the right therapeutic decision for each individual patient.
The pharmaceutical industry is committed to behaving in a responsible, ethical and professional manner. All of the promotional activities of the industry are subject to stringent legislation and rigorous Codes of Practice which cover all forms of promotion. The industry is committed to improving information and cooperating with all involved parties, such as doctors, regulators, pharmacists and patients, to ensure the appropriate use of medicines. IPHA has two Codes of Practice setting out detailed guidance to assist pharmaceutical companies in complying with the advertising legislation. They include the Code of Marketing Practice for the Pharmaceutical Industry and the Code of Advertising Standards for the Consumer Healthcare Industry both of which were revised and updated in 2008. The provisions of these Codes fully reflect the standards of the 2007 edition of the “European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the Promotion of Prescription-only Medicines to, and Interactions with, Healthcare Professionals� and incorporates changes arising from the Medicinal Products (Control of Advertising) Regulations 2007 (S.I. 541 of 2007).
12
DRIVEN BY HEALTH
IPHA Codes of Practice.
Medicines Safety Pharmaceutical companies have long understood the special responsibility they have to the people who use their medicines and the importance of operating to the highest possible ethical standards as well as to strict regulatory requirements.
In an ideal world, a medicine would target only the disease or disorder it is meant to treat and never do anything else; the so called ‘magic bullet’. However, despite the best efforts of medical experts and scientists, such a medicine does not yet exist. All medicines are associated with the risk of a possible adverse effect. New knowledge about those risks is revealed throughout the life of a medicine. Through comprehensive surveillance programmes pharmaceutical companies monitor, collect, analyse, and report all safety information associated with the use of medicines as well as communicate the adverse effects and safety profile to those concerned thus maximising patient safety.
Case Study: Ensuring healthcare professionals have the correct medicines information
Case Study: Securing the medicines supply chain
IPHA supports healthcare professionals’ work and helps to ensure the safe and effective use of medicines by producing the IPHA Medicines Compendium and www.medicines.ie. These provide independent, regulatory authority approved information on over 2,000 medicines currently on the market. The CD and website are provided free of charge to all GPs, Consultants, community and hospital pharmacists in Ireland. They allow the user to learn more about the correct use of medicines – such as what the possible side effects of any medication might be and how a particular medicine might interact with another.
In general, products on the market in Europe are safe and are sold in a controlled and highly regulated environment, i.e. through pharmacies. Nevertheless, there is a potential risk that a counterfeit product may reach the European market, mainly from outside Europe. While Internet-based sales are the main source of counterfeit medicines, these products are also appearing in the traditional supply chain. Counterfeits have been found to contain toxic substances. Others contain no active ingredient, or the wrong amount of it - damaging to any medical treatment, but dangerous when patients are being treated for serious illness. In most cases, it is impossible for the non-expert eye to distinguish the fakes from the originals. EFPIA is working to achieve a Europe-wide coding and identification system to combat counterfeiting. This should, if successful, contribute substantially to enhancing the safety and security of the medicines supply chain.
13
14 14
DRIVEN BY HEALTH
Support for Patients and Patient Organisations Many pharmaceutical companies have supported patient organisations activities in representing, meeting the information needs of and offering support to people living with ill-health. They realise that they share common interests and can benefit from working together towards achieving early diagnosis and appropriate treatment of an illness, improved compliance with treatment and better health outcomes.
In recent years pharmaceutical companies have run disease awareness campaigns in conjunction with patient organisations. These campaigns have broadly encouraged patients to seek medical help for conditions which they thought were untreatable, were subject to stigma or taboo (such as sexually transmissible diseases) or simply too embarrassing (e.g. impotence). When it comes to serious, life-threatening and quality-of-life-threatening diseases, such as diabetes, lack of patient knowledge can lead to problems. This motivates them to seek help and advice from healthcare professionals for symptoms they have simply been tolerating, for serious conditions they didn’t know they had, or for conditions they thought untreatable.
which is incorporated in the IPHA Code of Marketing Practice for the Pharmaceutical Industry (Annex III) In March 2008 IPHA established the IPHA Patient Forum which provides a platform where broader issues in the area of health and innovative medical research may be discussed between patient organisation representatives and the pharmaceutical industry. It works towards increasing understanding within the industry of patients’ perspectives and needs, and within patients’ organisations of the industry’s perspective and needs.
To help ensure that the collaboration between patient organisations and pharmaceutical companies continues to be positive, constructive, mutually beneficial, ethical and transparent, IPHA following consultation with patient organisations, developed guidance for pharmaceutical companies on working with them
Pictured opposite: ‘Junior Nurse’ Ms Emma McLoughlin at the launch of the IPHA ‘Knowledge is the Best Medicine’ campaign to educate patients on the appropriate use of medication.
15
Local
Case studies
Case study: Building knowledge and understanding of osteoporosis
Case Study: Art Against Stigma
The Joint Initiative on Bone Health (JIBH) was established to build knowledge and understanding of osteoporosis. Established in 2004 it facilitates a partnership built on mutual respect and trust between physicians and the Alliance for Better Bone Health (ABBH) composed of sanofi-aventis Ireland and Procter and Gamble Pharmaceuticals.
Since 2000, Lundbeck Ireland has supported events aimed at promoting visual art as a means of rehabilitation for individuals who have suffered mental illness by giving them a positive means of self-expression and promoting a better understanding of sufferers in the community.. These include the Lundbeck Art Awards, The Asylum Project and the Lundbeck Art Against Stigma project, which is now in its ninth year.
The partnership helps provide support and resources to improve care for those affected by the condition. The JIBH programme provides a forum to raise the profile of osteoporosis and reduce the burden of the disease for the patient and for the Irish healthcare system. The initiative comprises of leaders in the field of osteoporosis and supports developing knowledge and learning, educating colleagues and influencing the development of health strategy. The ABBH supports the JIBH members in their pursuit of best practice in managing osteoporosis through continuing professional development, service improvement, guideline implementation, educational meetings and other activities. It provides a forum for debate, a platform for examining and developing appropriate research, and an opportunity to build networks for collaboration to improve the quality of healthcare in the field. It also supports developing and implementing projects and initiatives which seek to improve healthcare in the field of osteoporosis
16
DRIVEN BY HEALTH
Consultant Psychiatrist, Dr Patricia Noone commented that “The Lundbeck Art Initiative is a very powerful tool as it gives people with mental illness self-confidence and self-belief, enabling them to express themselves through art, which is very important in helping them in their treatment”. “Expression through the medium of art can serve to enhance the life experience of many users of the mental health services and we believe that the works produced by these patients should be seen by others”, said, Eithne Boyan, Managing Director, Lundbeck Ireland. Each year the work of participants is shown in three regional exhibitions which aim to de-stigmatise mental illness. In 2007, Lundbeck won the ‘Most Innovative and Creative Collaboration’ prize in the Allianz Business2Arts Awards for their ‘Art Against Stigma’ Initiative.
Case study: Providing a guide to medicines for patients and their families Recognising its responsibility to inform patients and their carers about medicines, the IPHA developed www.medicines.ie. The site is a free service that enables people to find out more about the medicines they take. Covering prescription and nonprescription medicines, www.medicines.ie provides them with comprehensive, independently approved information on medicines available in Ireland today. The easy-to-use website means that one can access information on the correct use of their medicines, check the possible side effects, and find out more about the correct storage and use of medicines.
Allowing those suffering from mental illness a greater means of self-expression, the Lundbeck Art Initiative, has resulted in amazing works such as this piece titled ‘Just Another Tear’.
Medicines.ie, the IPHA medicines information online resource, logo.
17
Local
Case studies
Case Study: Inspiring people with RA to remain in or re-engage with work
In 2007, Abbott Laboratories, in collaboration with Arthritis Ireland, launched the RA Work a Day programme aimed at raising awareness of Rheumatoid Arthritis (RA) among the general public and employers, as well as to highlight the positive impact that new therapies are having on the disease. It also aimed to educate, empower and inspire people with rheumatic conditions to remain in or re-engage with work. RA is a chronic, autoimmune disease characterised by joint inflammation, joint pain and stiffness, which can lead to long-term joint damage. Almost 40,000 people in Ireland have RA and many of them are in the prime of their working lives. RA sufferers were invited to enter a competition to win the chance to spend a day in their dream job with a dream host. Some of Ireland’s best known personalities across a number of disciplines, (fashion, broadcasting, design and cookery), were engaged in the programme to host a patient for a day at work. Each of the 12 selected participants was photographed in their dream
18
DRIVEN BY HEALTH
job and their photograph was published in the 2008 Arthritis Ireland calendar. For those who were selected to experience “a day at work” in a unique environment with an Irish celebrity it was a very positive and rewarding experience. The work placement day also engaged employers and connected them to people with RA. The programme attracted huge recognition in the media and raised awareness of RA and the impact of new treatments. Each work placement created twelve unique stories which educated and inspired people with arthritis. Rheumatology clinics around the country were also presented with framed photographs of the participants in action. Inspired by the actions of those who participated in the RA Work a Day programme more people with arthritis came forward to register and participate in the Working with Arthritis training programme which Abbott Laboratories, Arthritis Ireland and FÁS developed as a follow-up. The first of these training programmes ran in June 2008 and was oversubscribed.
Ms Frankie Scott with Mr Graham Cruz at the Festival of World Cultures during her RA Work a Day.
Pictured opposite: Ms Ann Corish with Derby winner High Chaparral at Coolmore Stud during her RA Work a Day.
19
Local
Case studies
Case Study: Eli Lilly Solutions for Wellness
Case Study: Encouraging Irish people to monitor their blood pressure
Case study: Bringing a global drive to change diabetes to Ireland
In 2002 Eli Lilly launched their award winning ‘Solutions for Wellness’ programme, a patient initiative which provides healthy living information, tools and support for people with mental illness. Patients with severe and persistent mental illness are at increased risk of weight gain and obesity due to various factors, including sedentary lifestyles, poor nutrition, and lack of access to adequate medical care, nutritional and exercise programs. In addition, many medications used to treat mental illness may cause weight gain.
World Hypertension Day was held on Saturday 17th May 2008 and to recognise the occasion, Novartis Ireland sponsored blood pressure monitoring stations throughout Dublin to encourage people to be more proactive in achieving and maintaining a healthy blood pressure level.
Novo Nordisk believes that changes in attitude can prevent diabetes. Travelling across the globe, the Novo Nordisk Changing Diabetes Bus aimed to raise awareness to help overcome one of the world’s most pressing healthcare crises.
The ‘Solutions for Wellness’ programme is designed to work with doctor’s treatment plans and patient’s medication and is endorsed by Schizophrenia Ireland and the Irish College of Psychiatrists. Currently the programme is running in 300 centres around Ireland. The programme provides materials and publications for acute, community and individual programmes to address the implications of unbalanced diet and low activity levels. The community programme consists of weekly group sessions which are led by trained healthcare professionals.
20
DRIVEN BY HEALTH
The World Hypertension Day initiative was undertaken by the World Hypertension League and was supported by Novartis Ireland. Prof John Feely, Consultant Physician in Pharmacology and Therapeutics, Trinity College Dublin facilitated the Novartis initiative by providing medical students to man the Blood Pressure Monitoring Stations. The students took people’s blood pressure and advised them as appropriate. Information leaflets on hypertension were distributed along with pieces of fruit to encourage the nation to enjoy a healthy diet. There was an overwhelming public response to the initiative and an estimated 1,200 people lined up to have their blood pressure checked.
The bus visited numerous countries around the world in 2007 including Ireland from 15 to 18 October. It stopped in several cities opening up to everybody, from those who knew nothing about diabetes to healthcare professionals, as well as local politicians and government officials. Visitors received complementary health screenings, educational materials, tips for healthy living activities and free healthy refreshments. The ultimate goal was that from the time the Changing Diabetes Bus left Denmark in September 2006 to the time it arrived to New York City on the first-ever UN-observed World Diabetes Day (14th November 2007), it would have succeeded in reaching 1 billion people around the world with diabetes action messages. It achieved that objective!
Ms Loretto Callaghan, Novartis with a Trinity Medical Student and Taoiseach Brian Cowen at the launch of World Hypertension Day.
A selection of content from the Eli Lilly ‘Solutions for Wellness’ programme.
The Novo Nordisk Diabetes Bus arrived in Dublin on the 15th October 2007 as part of its ‘Changing Diabetes’ World Tour.
21
Local
Patient Compliance Medicines are only effective if used properly. Pharmaceutical companies produce materials for distribution after their medicine has been prescribed to help patients to use their medicines correctly. They do this in a variety of ways; for example, by explaining simply what the condition is, what the medicine does and the importance of using it properly, by providing advice and aids on self administration techniques where, e.g. eye drops or inhalers, are involved, by providing memory aids for dose timing and by providing self-help advice and support.
Case study: Education ensures compliance Recognising its responsibility to ensure people take their medicines correctly, IPHA has in conjunction with the Department of Health and Children, Health Service Executive and the representative body of community pharmacists, the Irish Pharmacy Union (IPU), developed various information booklets and consumer education campaigns. An ‘Ask about Your Medicines’ campaign was run in the spring of 2005 and involved media advertising, information leaflets and the booklet ‘Tips for Taking Medicines’. In August 2007 IPHA ran a therapy specific campaign with the IPU entitled ‘Ask Your Pharmacist about Pain Relief’. This was supported by a further campaign entitled ‘A little bit of knowledge can help you feel better, faster’ in 2007, which was conducted in association with the IPU and the Health Service Executive and included a detailed booklet and a dedicated website supported by posters displayed in pharmacies,
22
DRIVEN BY HEALTH
radio infomercials and a media launch which identified Ireland as having the highest incidence of minor ailments in Europe. In September 2008 IPHA ran a campaign aimed at helping older people know more about their medicines. This campaign was conducted in association with the IPU and Age Action Ireland and included an information booklet which encouraged older people to “Master Your Medicines” and to make them aware that medicines help was available from their local pharmacy. The key messages across all these campaigns have been: use medicines responsibly and correctly; read the instructions carefully; always take the correct dose; check expiry dates; ask your pharmacist (or doctor) if you have any questions about your medicine.
Visit: www.feelbetter.ie
Pictured opposite: Members of the Lucan Retirement Group at the launch of the ‘Master Your Medicines’ campaign 2008.
23
Local
Case studies
Case study: Merck Sharp & Dohme Crystal Clear Awards The Crystal Clear health literacy campaign is a collaborative project between the National Adult Literacy Agency (NALA) and Merck Sharp & Dohme Ireland (Human Health) Ltd. Health literacy is the capacity to make sound health decisions in the context of everyday life; at home, in the community and in the workplace.
“MSD believes that clear information and effective communications are the key to help patients understand more about their health. One of MSD’s core values is “Where Patients Come First” and we as a company are committed to driving change in this area so that all patients have access to relevant information and can participate more fully in their health decisions” said Ciara O’Rourke, External Affairs Director, MSD.
The Crystal Clear Awards were launched in 2007 to address the concern that people are not making informed decisions about their health. With over 50% of the Irish population affected in some way by literacy difficulties, it is inevitable that this is having a huge effect on the general public’s level of understanding of patient literature, their ability to make informed decisions about their own health and most importantly their understanding of how and when to take their medicines.
“We see the awards as an opportunity to recognise those individuals and organisations within the health field that have already made great strides in the area of health literacy across education and training, health writing, and patient communications. Our purpose is to recognise their great efforts and hope their examples will encourage others to consider developing their own initiatives to improve the level of informed decision making by patients” continued Ms O’Rourke.
MSD is committed to empowering patients by making information accessible to them. International research has found that patients who are better informed about their health have more effective consultations with their health care provider, are better informed about the medicines they are prescribed and are more involved in their healthcare decisions. Armed with this greater understanding; patients are more likely to comply with their medication and as a result have improved health outcomes.
24
DRIVEN BY HEALTH
Health literacy is a long-term commitment for MSD. In 2008 the company announced the sponsorship of a PhD research project, in collaboration with UCD School of Business, to address the lack of Irish specific data available. The study will seek to measure health literacy in Ireland and assess the impact of culture and of language on this area. Developing an instrument of measuring the economic implications of health literacy will also form part of the research.
The winners from the MSD Crystal Clear Awards 2008.
25
Local
Community Wherever located in Ireland, pharmaceutical companies aim to make a positive contribution to their local communities through charitable donations, volunteering, sponsorships and other initiatives that help to make a difference. In particular, company’s focus on bringing benefit that is consistent with their business of improving health and quality of life
Case Study: Volunteering at Wyeth Community involvement and volunteering has become an important asset in support of Wyeth’s corporate vision and is a critical component of its CSR programme. Wyeth employees, of whom there are 3,000 in Ireland, are vocal about their desire to be involved with their communities and encourage Wyeth to support organisations and causes that benefit those in which they live and work. Wyeth has taken an innovative approach to volunteering, providing dedicated support and resources and actively encouraging employees to share their skills and experience with their communities. They strive to connect with local communities and the end result is a varied and exciting volunteering programme which is fully supported by the company through the availability of time and financial resources.
Give It A Swirl Day, the national day of volunteering took place on the 28th September 2008. Wyeth is the lead corporate sponsor of this exciting initiative. 180 Wyeth employees participated in a vast range of projects, including mucking out stables in Fettercairn Youth Horse Project, donating blood, teaching computers in Peamount Hospital, bowling with a group of local teenagers, coordinating a trip to the zoo for Stewarts Hospital clients, gardening at Cheshire Respite Home and fasting for 24 hours in a bid to raise funds for The Hope Foundation. Challenge Science Roadshow introduced students to a world of creation and discovery and illustrates the importance of science in today’s world of work. 16 volunteers delivered structured interactive modules to 75 students over two days in Tallaght Institute of Technology.
Volunteering boosts employees’ morale by demonstrating a social commitment. It enhances teamwork and cross functional collaboration through participation in volunteer activities with colleagues and community partners. In line with Wyeth’s commitment to employee development volunteers are exposed to wide range of learning experiences – team work, planning, inter-personal skills and communication skills.
Junior Achievement Ireland programmes helps to create a culture of enterprise within the education system. Volunteers spend one hour per week for six weeks in the classroom delivering programmes to students. During the 2007/2008 school year 70 Wyeth employees delivered programmes to over 1,700 students.
Over a twelve month period, Wyeth employees volunteer in excess of 2,000 hours of their time to support numerous organisations and events.
Pictured opposite: A student enjoying herself during the Wyeth Challenge Science Roadshow in the Tallaght Institute of Technology.
26
DRIVEN BY HEALTH
27
Local
Case studies
Case Study: Way2Go for a Healthier You – an anti-obesity initiative Pfizer Healthcare Ireland partnered with the Department of Education & Science, the Irish Heart Foundation, Dublin City University, and the National Parents Council Primary, to develop the ‘Way 2 Go for a healthier you!’ programme. The aim of the project was to highlight and address the rising problem of obesity in Ireland. The then Minister for Education & Science, Mary Hanafin, TD, said: “There is plenty of debate about healthy eating and lifestyle. Way2Go provides practical advice on how to make changes for a healthier lifestyle. The Social Personal and Health Education (SPHE) programme places teachers central in this process, along with parents and children. Way2Go is consistent with the advice of the National Obesity Task Force which recommends that schools promote healthy eating and active living. Children and young adults can choose to act now and develop
28
DRIVEN BY HEALTH
healthy habits that will stay with them for their lifetime and have the benefit of feeling and looking well.” In consultation with psychologists, nutritionists, academics and experts in physical activity, booklets, workbooks, a DVD and a teachers’ guide were developed and sent to every secondary school in the country. With one in five Irish children classified as overweight and one in 20 clinically obese, Way2Go offers practical steps on nutrition, activity, emotional wellbeing and communication that can make a real difference to every member of the family. All of the messages in the programme are positive and aimed at effecting behavioural change through the utilising of new manageable strategies, which can be easily implemented in the home by both parents and children. Way2Go won the Chambers Ireland President’s award for Best New and Innovative CSR programme for 2006.
Psychologist, Dr Mark Harrold with then Education Minister, Ms Mary Hanafin TD and nutritionist, Ms Paula Mee at the launch of ‘Way2Go’.
29
Local
Case studies
Case study: GlaxoSmithKline (GSK) Community IMPACT Awards In 2007, the GSK Community IMPACT Awards were established at their Dublin offices. This allowed both field and office based employees at GSK Dublin to nominate a local community project they were involved in for a Community Impact Award which awarded funding of either €1000 or €500. In total, €20,000 was awarded to schools, sports clubs, community centres, local charities etc through 30 awards all around the country. Charities included: The Order of Malta Templeogue; Hartstown / Huntstown Community Drugs Team Ltd; the Phoenix Youth Band Tallaght; Rathfarnham Parish Youth Club; St Kevin’s Football Club, Santry; The Voice of Westport Youth; Cathedral Cairdre, Cork; Carlow Autism Awareness Network; Ballymoe Development Centre and White Church National School Rathfarnham. Ms Eavan Daly, GSK presenting a cheque to the Boyne Fishermen’s Rescue Service as part of their GSK Community IMPACT Awards.
30
DRIVEN BY HEALTH
Committed to the communities in which its employees live and work GSK supports the above local girls’ soccer team in Ballinteer, Co. Dublin.
31
Local
Case studies
Case Study: Providing academic support in the community Since 2002 Leo Pharma sponsor three academic scholarships for disadvantaged students in their local community in order that they may further their education at third level. The scholarships are administered by the South Dublin Chamber of Commerce through its Schools Business Partnership Programme and have supported a number of promising students who otherwise might not have been able to pursue further education.
32
DRIVEN BY HEALTH
Case Study: IPHA Charitable Giving In the past 10 years IPHA has raised in excess of €210,000 for deserving causes through its charity events. Some of the organisations who have benefited from this support include Threshold, the Aisling Project, the Irish Hospice Foundation, the Niall Mellon Township Trust and the St John of God College of Mental Health Sciences Malawi. Brother Aidan Clohessy, Director of the St John of God Community Services in Malawi said: “The proceeds raised will be placed in the St John of God Mental Health Sciences Development Fund in order to provide education and training for mental health professionals. These clinicians will provide sustainable mental health services to people suffering psychological and emotional illnesses, including the effects of poverty and HIV/AIDS.” He also added that the assistance of the Irish pharmaceutical industry was deeply appreciated and that he would like to think that the IPHA’s efforts made people realise how the pharmaceutical industry is assisting the poor in developing countries. IPHA will continue to support organisations such as these in to the future.
Ms Anne Nolan, Chief Executive of the IPHA and Mr Michael Dempsey, former IPHA President (right), presenting a cheque for â‚Ź21,000 to Brother Laurence Kearns, St. John of God.
33
Local
Workplace The pharmaceutical industry strives to uphold high standards in the recruitment and retention of employees and the development of individuals, by adopting initiatives in the workplace that are intended to promote the industry as a sustainable employer of choice and provide a healthy, safe and energising work environment.
Pharmaceutical companies provide a wide range of training and development initiatives which give employees an opportunity to learn and progress within the pharmaceutical industry. Annual performance appraisals incorporate goal setting giving employees a clear sense of their contribution to their company’s success. They also include healthy living and well being initiatives which are designed to help promote physical and psychological welfare and to help employees cope with demanding jobs and busy lives. These include flexible working arrangements, access to fitness activities, healthy food options in canteens and proactive support for staff experiencing stress. Safety education programmes and health and safety days aim to eliminate all injuries and accidents to employees.
34
DRIVEN BY HEALTH
Case study: Watching out for each others heart The Irish Heart Foundation (IHF) runs an accreditation programme called ‘Heartsafe’. Pfizer Healthcare Ireland is the first company in Ireland to achieve ‘Heartsafe’ status across all Pfizer sites, having trained more than 900 colleagues in CPR and/or Automated External Defibrillator (AED) usage and they plan to maintain Heartsafe status through having a programme for ongoing training in place across all sites. There are four steps that the IHF recognise as being key in preventing death from cardiac arrest. These steps are: 1. Early Access 2. Early CPR 3. Early Defibrillation 4. Early Advanced Care. What ‘Heartsafe’ means in reality is that someone who suffers a cardiac incident is never more than 6-8 minutes away from an AED and someone who can operate it or someone who knows how to administer CPR.
Minister Micheal Martin TD with Ms Claire Murphy, Pfizer Healthcare Ireland and Dr Brian Maurer, Irish Heart Foundation.
35
Local
Case Studies
Case Study: Supporting health from within The Westport based pharmaceutical company Allergan Pharmaceuticals believes in contributing substantially to the health of its employees. -Everyday, healthy food choices are made available in the company restaurant. -Every employee is entitled to a full medical every two years while there is a company doctor onsite once a week. -Counselling services are available and all employees participate in a company health screening programme. -In 2007 Allergan engaged in a cancer awareness programme with the Marie Keating Foundation. While in addition to this they included a smoking cessation programme in 2008 to assist employees who wanted to quit smoking.
36
DRIVEN BY HEALTH
Allergan Pharmaceuticals Ireland is based in Westport, Co. Mayo.
Case study: Vehicle and driving safety Vehicles and road journeys represent one of the most recognised risks to employees in the pharmaceutical industry. For many employees, the company vehicle is a workplace. Driving related accidents are a particular problem with so many medical representatives driving extensively on company business. As such many pharmaceutical companies, including Astellas Pharma, conduct advanced driving programmes for employees with company vehicles in order to protect employees, families and customers from injury on the road.
Mr Stephen Dooley (left) presenting an advanced driving certificate to Mr Stephen Joyce on successful completion of the Astellas Pharma advanced driving programme.
Some companies also recognise and reward good driving records in order to motivate safe behaviour.
37
Further Information
38
DRIVEN BY HEALTH
PharmaChemical Ireland Responsible Care Report
IFPMA Partnerships to Build Healthier Societies in the Developing World
Responsible Care is a chemical industry initiative incorporating pharmaceutical companies which calls on companies to demonstrate their commitment to improve all aspects of performance which relate to protection of health, safety and the environment. Responsible Care was launched in Ireland in June 1992.
The Partnerships to Build Healthier Societies in the Developing World provides an overview of long-term health development programmes implemented by the international research-based pharmaceutical industry and partners to help achieve the health-related Millennium Development Goals and improve global health.
www.pharmachemicalireland.ie
www.ifpma.org/healthpartnerships
Member Companies A Menarini Pharmaceuticals Ireland Ltd
www.menarini.com
Abbott Laboratories (I) Ltd
www.abbott.com
Allergan Laboratories (I) Ltd
www.allergan.co.uk
Alliance Pharmaceuticals Ireland
www.alliancepharma.co.uk
Amgen Ireland Limited
www.amgen.com
Astellas Pharma Ltd
www.astellas.com
AstraZeneca Pharmaceuticals (Ireland) Ltd
www.astrazeneca.ie
Bayer Consumer Care
www.bayer.ie
Bayer Schering Pharma
www.bayer.ie
Biogen Idec (Ireland) Ltd
www.biogenidec.com
Boehringer Ingelheim Ireland Limited
www.boehringer-ingelheim.ie
Bristol-Myers Squibb Pharmaceuticals
www.bmsireland.ie
Celgene Limited
www.celgene.com
Cephalon Pharma (Ireland) Limited
www.cephalon.com
Eisai Limited
www.eisai.com
Eli Lilly & Company (Ireland) Ltd
www.lilly.ie
GlaxoSmithKline
www.gsk.com
GlaxoSmithKline Consumer Healthcare
www.gsk.com
Grunenthal Pharma Ltd
www.grunenthal.ie
Helsinn Birex Therapeutics Ltd
www.helsinn.com
Ipsen Pharmaceuticals Limited
www.ipsen.ie
Janssen-Cilag Limited
www.janssen-cilag.ie
Labropharm Europe Limited
www.labopharm.com
LEO Pharma
www.leo.ie
Lundbeck (Ireland) Ltd
www.lundbeck.ie
McNeil Healthcare
www.jnj.com
MEDA
www.meda.se
Merck Serono
www.merck.ie
Merck Sharp & Dohme Ireland (Human Health) Ltd
www.msd-ireland.com
Mundipharma Pharmaceuticals Company
www.mundipharma.ie
Novartis Consumer Health
www.ie.novartis.com
39
Member Companies
Novartis Ireland Ltd
www.ie.novartis.com
Novo Nordisk Limited
www.novonordisk.ie
Nycomed Products Ltd
www.altanapharma.ie
Organon Laboratories Limited
www.organon.ie
Pfizer Healthcare Ireland
www.pfizer.ie
Pierre Fabre Ltd
www.pierre-fabre.com
Procter and Gamble
www.pg.com
Reckitt Benckiser (Ireland) Ltd
www.reckitt.com
Roche Products (Ireland) Ltd
www.roche.ie
Rottapharm Ltd
www.rotta.com
sanofi-aventis Ireland Ltd
www.sanofi-aventis.ie
sanofi Pasteur MSD
www.spmsd.ie
Schering Plough Pharmaceuticals (Ireland) Limited
www.schering-plough.com
Servier Laboratories (Ireland) Limited
www.servier.ie
Shire Pharmaceuticals Ireland Ltd
www.shire.com
Solvay Healthcare Limited
www.solvay.com
SSL Healthcare Ireland Ltd
www.ssl-international.com
Stiefel Laboratories
www.stiefel.com
Tillotts Pharma Ltd
www.tillotts.com
UCB Pharma Limited
www.ucb.com
Wyeth Consumer Healthcare
www.wyeth.ie
Wyeth Pharmaceuticals
www.wyeth.ie
40
DRIVEN BY HEALTH
Irish Pharmaceutical Healthcare Association Ltd Franklin House 140 Pembroke Road Dublin 4 Ireland T (+353 1) 660 3350 F (+353 1) 668 6672 E info@ipha.ie www.ipha.ie www.medicines.ie www.feelbetter.ie